全文获取类型
收费全文 | 1728篇 |
免费 | 134篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 36篇 |
妇产科学 | 26篇 |
基础医学 | 194篇 |
口腔科学 | 19篇 |
临床医学 | 283篇 |
内科学 | 378篇 |
皮肤病学 | 51篇 |
神经病学 | 109篇 |
特种医学 | 36篇 |
外科学 | 314篇 |
综合类 | 12篇 |
一般理论 | 4篇 |
预防医学 | 164篇 |
眼科学 | 13篇 |
药学 | 153篇 |
肿瘤学 | 60篇 |
出版年
2023年 | 34篇 |
2022年 | 26篇 |
2021年 | 60篇 |
2020年 | 31篇 |
2019年 | 75篇 |
2018年 | 82篇 |
2017年 | 54篇 |
2016年 | 47篇 |
2015年 | 50篇 |
2014年 | 78篇 |
2013年 | 93篇 |
2012年 | 132篇 |
2011年 | 144篇 |
2010年 | 83篇 |
2009年 | 82篇 |
2008年 | 97篇 |
2007年 | 99篇 |
2006年 | 95篇 |
2005年 | 67篇 |
2004年 | 85篇 |
2003年 | 63篇 |
2002年 | 64篇 |
2001年 | 14篇 |
2000年 | 13篇 |
1999年 | 12篇 |
1998年 | 13篇 |
1997年 | 7篇 |
1996年 | 10篇 |
1995年 | 11篇 |
1994年 | 5篇 |
1993年 | 5篇 |
1992年 | 7篇 |
1990年 | 7篇 |
1989年 | 5篇 |
1988年 | 8篇 |
1987年 | 4篇 |
1985年 | 9篇 |
1984年 | 11篇 |
1983年 | 15篇 |
1982年 | 5篇 |
1981年 | 4篇 |
1979年 | 4篇 |
1978年 | 4篇 |
1977年 | 7篇 |
1976年 | 4篇 |
1975年 | 3篇 |
1974年 | 3篇 |
1973年 | 3篇 |
1969年 | 3篇 |
1936年 | 4篇 |
排序方式: 共有1865条查询结果,搜索用时 15 毫秒
61.
Jacqueline Soraru Nicole Isbel Germaine Wong Patrick Toby Coates Murty Mantha Abu Abraham Rajiv Juneja Danny Hsu Fiona Brown Bhadran Bose David Mudge Robert Carroll Joshua Kausman Peter Hughes Thomas Barbour Anne Durkan Peter Mount Darren Lee Nicholas Larkins Dwarakanathan Ranganathan Wai H. Lim 《Nephrology (Carlton, Vic.)》2020,25(9):683-690
62.
63.
64.
65.
Min Ju Toby S Scott-Ward Jia Liu Pissared Khuituan Hongyu Li Zhiwei Cai Stephen M Husbands David N Sheppard 《British journal of pharmacology》2014,171(1):265-278
BACKGROUND AND PURPOSE
Loop diuretics are widely used to inhibit the Na+, K+, 2Cl− co-transporter, but they also inhibit the cystic fibrosis transmembrane conductance regulator (CFTR) Cl− channel. Here, we investigated the mechanism of CFTR inhibition by loop diuretics and explored the effects of chemical structure on channel blockade.EXPERIMENTAL APPROACH
Using the patch-clamp technique, we tested the effects of bumetanide, furosemide, piretanide and xipamide on recombinant wild-type human CFTR.KEY RESULTS
When added to the intracellular solution, loop diuretics inhibited CFTR Cl− currents with potency approaching that of glibenclamide, a widely used CFTR blocker with some structural similarity to loop diuretics. To begin to study the kinetics of channel blockade, we examined the time dependence of macroscopic current inhibition following a hyperpolarizing voltage step. Like glibenclamide, piretanide blockade of CFTR was time and voltage dependent. By contrast, furosemide blockade was voltage dependent, but time independent. Consistent with these data, furosemide blocked individual CFTR Cl− channels with ‘very fast’ speed and drug-induced blocking events overlapped brief channel closures, whereas piretanide inhibited individual channels with ‘intermediate’ speed and drug-induced blocking events were distinct from channel closures.CONCLUSIONS AND IMPLICATIONS
Structure–activity analysis of the loop diuretics suggests that the phenoxy group present in bumetanide and piretanide, but absent in furosemide and xipamide, might account for the different kinetics of channel block by locking loop diuretics within the intracellular vestibule of the CFTR pore. We conclude that loop diuretics are open-channel blockers of CFTR with distinct kinetics, affected by molecular dimensions and lipophilicity. 相似文献66.
Itsik Ben-Dor MD Avinash Sharma MD Toby Rogers MD PhD Charan Yerasi MD Brian C. Case MD Chava Chezar-Azerrad MD Anees Musallam MD Brian J. Forrestal MBBS Cheng Zhang PhD Hayder Hashim MD Nelson Bernardo MD Lowell F. Satler MD Ron Waksman MD 《Catheterization and cardiovascular interventions》2021,97(7):1379-1385
67.
Brian C. Case MD Sant Kumar BA Charan Yerasi MD Brian J. Forrestal MBBS Anees Musallam MD Chava Chezar-Azerrad MD Nauman Khalid MD Evan Shlofmitz DO Yuefeng Chen MD PhD Jaffar M. Khan BM BCh PhD Lowell F. Satler MD Itsik Ben-Dor MD Hayder Hashim MD Nelson L. Bernardo MD Toby Rogers MD PhD Ron Waksman MD 《Catheterization and cardiovascular interventions》2021,98(3):572-577
68.
ObjectiveTo determine the predictive markers for the occurrence of upper limb spasticity in the first 12 months after stroke.Data sourcesA systematic review was undertaken of the databases MEDLINE, EMBASE, CINAHL and PEDRO to 31st December 2017.Study selectionNon-experimental or experimental studies that included a control group with spasticity who did not receive an experimental intervention which investigated at least one variable (explanatory variable) measured at baseline against the development (or not) of spasticity at a future time point within 12 months post stroke were selected independently by two reviewers. Eleven papers met the selection criteria.Study appraisalData were extracted into tabular format using predefined data fields by two reviewers. Study quality was evaluated using the modified Downs and Black tool. Data were analysed using a meta-analysis or narrative review.ResultsTen studies, including 856 participants were analysed. The predictive markers of upper limb spasticity at one month post stroke were: motor 11.25 (odds ratio, OR); [95% CI:2.48, 51.04] and sensory impairments 4.91 (OR); [1.24, 19.46]; haemorrhagic stroke 3.70 (OR); [1.05, 12.98] and age 0.01 (OR) [0.00, 69.89]. Only motor impairment was found as a significant predictor at six months post stroke 30.68 (OR); [1.60, 587.06].LimitationsLow number of studies exploring biomechanical and neurophysiological in addition to behavioural predictors of spasticity were included.Conclusion and implications of key findingsUsing the results, the identified predictive markers have potential to better inform clinical decision-making and to plan specific rehabilitation interventions by physiotherapists for stroke survivors with upper limb spasticity.
Systematic Review Registration Number PROSPERO (ID: CRD42016027642). 相似文献
Systematic Review Registration Number PROSPERO (ID: CRD42016027642). 相似文献
69.
Toby O. Smith Rachel Purdy Sarah Lister Charlotte Salter Robert Fleetcroft Philip G Conaghan 《Rheumatology international》2014,34(3):299-313
This paper determines the perceptions of people diagnosed with osteoarthritis towards their conservative management strategies. A systematic review of the published (AMED, CINAHL, EMBASE, PsychINFO, SportsDisc, MEDLINE, Cochrane Clinical Trials Registry, PubMed) and unpublished/trial registry databases (WHO International Clinical Trials Registry Platform, Current Controlled Trials, the United States National Institute of Health Trials Registry, NIHR Clinical Research Portfolio Database) searched from their inception to July 2013. Eligible studies included those which presented the attitudes or perceptions of people with osteoarthritis towards non-operative management strategies. Study quality was appraised using the CASP and the Gough’s weight of evidence appraisal tools. Data were analysed through a meta-ethnography approach. Thirty-three studies including 1,314 people with osteoarthritis were sampled; the majority diagnosed with knee osteoarthritis. The overarching themes indicated people with osteoarthritis delay their diagnosis, opting for self-management and informal information gathering. This informal rather than health professional-led guidance is sought and maintained as an important resource throughout the care of this population and is valued. Diagnosis is sought at a ‘critical point’. Healthcare interventions largely provided are poorly perceived. The period of subsequent self-management is an expectation before the inevitable requirement for joint replacement. There remains uncertainty regarding when this is required, but the expected failure of conservative treatment to manage pain and symptoms is common. In conclusion, patients should be enthused towards the principles of self-management and clinicians should not trivialise osteoarthritis. This may provide a more valuable perception of non-operative management to promote its adoption and adherence in managing osteoarthritis. 相似文献
70.
Toby A. Eyre Lindsey E. Roeker Christopher P. Fox Satyen H. Gohill Renata Walewska Harriet S. Walter Francesco Forconi Angus Broom Arvind Arumainathan Danielle M. Brander John N. Allan Stephen J. Schuster Brian T. Hill Frederick Lansigan Bruce D. Cheson Nicole Lamanna Catherine C. Coombs Paul M. Barr Alan P. Skarbnik Mazyar Shadman Chaitra S. Ujjani Laurie Pearson John M. Pagel Ryan Jacobs Anthony R. Mato 《British journal of haematology》2020,188(6):918-923
Elderly chronic lymphocytic leukaemia (CLL) patients treated outside of trials have notably greater toxicity with the Bruton's tyrosine kinase inhibitor ibrutinib compared to younger patients. It is not known whether the same holds true for the B-cell lymphoma 2 inhibitor venetoclax. We provide a comprehensive analysis of key safety measures and efficacy in 342 patients comparing age categories ≥75 and <75 years treated in the relapsed, refractory non-trial setting. We demonstrate that venetoclax has equivalent efficacy and safety in relapsed/refractory CLL patients who are elderly, the majority of whom are previous ibrutinib-exposed and therefore may otherwise have few clear therapeutic options. 相似文献